AN ORGANIZATION STUDY

GLAXOSMITHKLINE Presented by:-

Mr. Mehsum Ali Mr. Ali Ather Mohsin

Mr.Mohammad Arif Mr. Taj-ud-din Mr. Muhammad Ali

Hashmi

Introduction and Background Vision and Mission Product line GSK Management Organizational Chart Management Levels SWOT Analysis Porter’s Strategies Questions and Answers

GlaxoSmithKline plc (LSE: GSK NYSE: GSK), often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's Fourth largest pharmaceutical company measured by revenues (after Johnson & Johnson, Pfizer & Roche.

GSK was formed in 2000 by the merger of GlaxoWellcome plc (formed from the acquisition of Wellcome plc by Glaxo plc), and SmithKline Beecham plc (from the merger of Beecham plc, and SmithKlineBeckman Corporation).

GlaxoSmithKline Pakistan Limited came into existence after the merger of Smith Kline and French of Pakistan Limited and Beecham Pakistan (Private) Limited with Glaxo Wellcome Pakistan Limited in 2002. It is listed on the Karachi and Lahore stock exchanges. GSK has a large portfolio of products ranging tablets, toothpaste, inhalers and complex capsules in over 28,000 different pack sizes and presentations.

“The opportunity to make a difference to the lives of billions of people”.

GlaxoSmithKline has a challenging and inspiring mission their mission is to improve the quality of human life by enabling people to do more, feel better and live longer

The company is managed by the Board of Directors and the Corporate Executive Team.

The Board is comprised of executive and non-executive directors who are responsible for their corporate governance and ultimately accountable for their activities, strategy and performance.

The Chief Executive Officer (CEO) is responsible for the management of the business and is assisted by the Corporate Executive Team that manages their activities. Each member is responsible for a specific part of the business.

ORGANIZATIONAL CHARTORGANIZATIONAL CHART

The management levels of GSK are as follows:-

Executive-Level Director-Level Manager-Level Staff

Strengths:Strong Management TeamLarge Market ShareHighest research Products in PakistanWide range of Products

Weaknesses:No online presence in PakistanStrong focus on UK market (losing opportunities in Pakistan)Less checking on the sales representatives for their working in field

Opportunities:Emerging markets and expansion abroad Have great chance to cash its brand name in the field of surgical marketGSK can be able to cash its name in baby foods

Threats:Lower cost competitors or imports like Chinese and Indian medicines etcPatent expiry on drugs that generate strong incomeIncreasing cost of drug trials (research) and ever higher standards imposed by national drug approvals bodies.

TO GROW A DIVERSIFIED GLOBAL BUSINESS.

DELIVER VALUE PRODUCTS

SIMPLIFYING THE OPERATING MODEL

CHALLENGING AND INSPIRING MISSION

LONG TERM INCENTIVE PLAN

Increase growth in the pharmaceutical business in its core market.

GSK is diversifying its business to bring balance in product portfolio & go away from a reliance on traditional markets.

GSK expects to generate future sales growth by strengthening its core pharmaceutical business & supplementing it with increased investment in growth such as; vaccines, dermatology and consumer health care.

Business expansion inn Japan Build a leadership in dermatology.

Focusing on the best science

Focus on research and development

Diversifying the level of externalization in research to focus on disease area, where GSK believe the prospects for successful registration and launch of differentiated medicines.

As GSK continue to change shape, so it is essential that reduce the complexities in operating model, improve efficiencies and reduce cost.

Re-shape manufacturing

GSK has a challenging vision and mission is to improve the quality of human life by making people to do more, feel better and live longer.

Long term incentive plan. awards are made to executives under the

following long term incentive plan, i) Deferred annual bonus planii) Performance share plan

Explanation: Deferred Annual bonus plan: The deferred annual bonus plan

encourages long term shareholding, discourages excessive risk taking and help focus on GSK’S key strategic priorities.

Performance share : the performance share plan ensure focus on the delivery of GSK’S strategic priorities and long term share holders returns relative to other pharmaceutical companies.

Meeting with DR. AHMED FARHAN

Questionnaire MANAGER AND STAFF

Interview DR. AHMED FARHAN

GSK annual report 2011.

www.gsk.com

Term report of GSK

Wikipedia,2011